Dr. Jiahong Zhao is a distinguished clinical research leader specializing in innovative drug development and regulatory science. He currently serves as Chief Medical Officer, Vice President, and Board Member at CGeneTech (Suzhou) Co., Ltd., and holds specially appointed professorships at Jiangsu University and Zhejiang Chinese Medical University.

Dr. Zhao has led or participated in over 600 clinical research projects, with deep expertise spanning Phase I–III clinical trials and international multicenter studies. His work encompasses a broad range of therapeutic areas, including oncology, immunology, rare diseases, and metabolic disorders. He has been instrumental in designing innovative clinical trial strategies, such as adaptive trials, biomarker-driven studies, and first-in-human studies, enabling efficient evaluation of novel therapies and accelerated regulatory approval.

He has successfully advanced 26 innovative drug programs to regulatory approval and contributed to the assessment of cutting-edge therapies, including gene therapy, immuno-oncology agents, and biologics. Dr. Zhao has also played a key role in national regulatory initiatives, such as the “722 Storm” data verification and the Rare Disease Catalogue, supporting high-quality, compliant clinical research standards in China.

Previously, Dr. Zhao held senior leadership positions in the pharmaceutical industry, including Chief Medical Officer at Jiangxi Jemincare Group, Vice President at Beijing Highthink Pharmaceutical Technology, and Director of R&D at Tigermed, and Vice President of the Tigermed Medical Research Institute. He earned his Doctorate from Fudan University, has published more than 30 scientific papers, and authored two academic monographs.